Clinical trials, whether industry, cooperative group sponsored, or investigator initiated, have
an unacceptable rate of failure as a result of the inability to recruit sufficient numbers of …

Background Clinical trials that study cancer are essential for testing the safety and
effectiveness of promising treatments, but most people with cancer never enroll in a clinical …

Randomized control trials (RCTs) are required before drug and device approvals and have
contributed to patient safety, but they have also increased the cost and time of regulatory …

Background Ethical evaluation of risk–benefit in clinical trials is premised on the
achievability of resolving research questions motivating an investigation. Objective To …

The number and diversity of cancer therapeutics in the pipeline has increased over the past
decade due to an enhanced understanding of cancer biology and the identification of novel …

Abstract The Accrual to Clinical Trials (ACT) network is a federated network of sites from the
National Clinical and Translational Science Award (CTSA) Consortium that has been …

Purpose: Cancer clinical trials often accrue slowly or miss enrollment targets. Strict eligibility
criteria are a major reason. Restrictive criteria also limit opportunities for patient participation …

Purpose The authors assessed the prevalence and associated economic impact of low-
enrolling clinical studies at a single academic medical center. Method The authors …

Purpose The comprehensive complication index (CCI) is a new tool for reporting the
cumulative burden of postoperative complications on a continuous scale. This study …

Advances in 'omics' technology and targeted therapeutic molecules are together driving the
incorporation of molecular-based diagnostics into the care of patients with cancer. There is …